Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K, 2005. Malaria risk in travelers. Emerg Infect Dis 11 :436–441.
-
2
Ranque S, Marchou B, Malvy D, Adehossi E, Laganier R, Tissot-Dupont H, Lotte A, Dydymsky S, Durant J, Stahl JP, Bosseray A, Gaillat J, Sotto A, Cazorla C, Ragneau JM, Brouqui P, Delmont J, Infectio-Sud Group, 2005. Treatment of imported malaria in adults: a multicentre study in France. QJM 98 :737–743.
-
3
Bradley DJ, Bannister B, 2003. Health protection Agency Advisory Committee on malaria prevention for UK travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Public Health 6 :180–199.
-
4
Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, Vranjes N, Bergqvist Y, Ericsson O, Hellgren U, Rombo L, Mannino S, Handschin J, Sturchler D, 1996. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments: stereochemistry and compliance. Trop Med Int Health 1 :485–494.
-
5
Patel SN, Kain KC, 2005. Atovaquone-proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther 3 :849–861.
-
6
Mayxay M, Khanthavong M, Lindegardh N, Kiola S, Barends M, Pongvongsa T, Yapon R, Annerberg A, Phompida S, Phetsouvan R, White NJ, Newton PN, 2004. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether- lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic. Clin Infect Dis 39 :1139–1147.
-
7
Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R, 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug–resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 64 :247–256.
-
8
Van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ, 1999. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 61 :964–967.
-
9
Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Treeprasertsuk S, Kano S, Brittenham GM, Looareesuwan S, 2003. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian Public Health. 34 :316–321.
-
10
Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI, 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99 :459–467.
-
11
Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, Bosman A, Moyou-Somo R, Nahimana A, Nyarushatsi JP, Barihuta T, Mizero L, Ndaruhutse J, Delacollette C, Ringwald P, Kamana J, 2004. Efficacy of artemisinin derivative combination therapy for the treatment of uncomplicated falciparum malaria in Burundi; Efficacité de combinaisons thérapeutiques avec des dérivés de lart ’ émisinine dans le traitement de l’accès palustre non-compliqué au Burundi. Trop Med Int Health 9 :673–679.
-
12
Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Björkman A, 2005. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41 :1079–1086.
-
13
Mutabingwa TK, Anthony D, Heller A, Hallet R, Ahmed J, Drakely C, Greenwood BM, Whitty CJM, 2005. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodia-quine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 :1476–1482.
-
14
World Health Organization, 2000. Management of Severe Malaria. A Practical Handbook. Second Edition. Geneva: World Health Organization.
-
15
Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J, 1998. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129 :241–244.
-
16
Bazett JC, 1920. An analysis of time relation of electrocardiograms. Heart 7 :353–367.
-
17
Fridericia LS, 2003. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 8 :343–351.
-
18
Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, Chongsuphajaisiddhi T, White N, 2001. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg 65 :614–622.
-
19
Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M, 2000. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 56 :375–381.
-
20
Krippner R, Staples J, 2003. Suspected allergy to artemether-lumefantrine treatment of malaria. J Travel Med 10 :303–305.
-
21
Vatan R, Pistone T, Millet P, Etienne G, Mercie P, Longy-Boursier M, Malvy D, 2006. Retrospective analysis of 107 imported adult cases of malaria. Experience report of uncomplicated falciparum malaria treatment in adults with oral atovaquone-proguanil. Presse Med. Apr 35 :571–577.
-
22
Hitani A, Nakamura T, Ohtomo H, Nawa Y, Kimura M, 2006. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan. J Infect Chemother 12 :277–282.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 44 | 44 | 12 |
| Full Text Views | 323 | 115 | 2 |
| PDF Downloads | 144 | 55 | 4 |
Treatment of Acute Uncomplicated Falciparum Malaria with Artemether-Lumefantrine in Non-immune Populations: A Safety, Efficacy, and Pharmacokinetic Study
Christoph Hatz
Christoph Hatz
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Christoph Hatz in
Current site
Google Scholar
PubMed
Search for other papers by Christoph Hatz in
Current site
Google Scholar
PubMed
Jaime Soto
Jaime Soto
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Hans Dieter Nothdurft
Hans Dieter Nothdurft
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Hans Dieter Nothdurft in
Current site
Google Scholar
PubMed
Search for other papers by Hans Dieter Nothdurft in
Current site
Google Scholar
PubMed
Thomas Zoller
Thomas Zoller
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Thomas Zoller in
Current site
Google Scholar
PubMed
Search for other papers by Thomas Zoller in
Current site
Google Scholar
PubMed
Thomas Weitzel
Thomas Weitzel
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Thomas Weitzel in
Current site
Google Scholar
PubMed
Search for other papers by Thomas Weitzel in
Current site
Google Scholar
PubMed
Louis Loutan
Louis Loutan
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Louis Loutan in
Current site
Google Scholar
PubMed
Search for other papers by Louis Loutan in
Current site
Google Scholar
PubMed
Francois Bricaire
Francois Bricaire
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Francois Bricaire in
Current site
Google Scholar
PubMed
Search for other papers by Francois Bricaire in
Current site
Google Scholar
PubMed
Frederick Gay
Frederick Gay
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Frederick Gay in
Current site
Google Scholar
PubMed
Search for other papers by Frederick Gay in
Current site
Google Scholar
PubMed
Gerd-Dieter Burchard
Gerd-Dieter Burchard
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Gerd-Dieter Burchard in
Current site
Google Scholar
PubMed
Search for other papers by Gerd-Dieter Burchard in
Current site
Google Scholar
PubMed
Kim Andriano
Kim Andriano
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Kim Andriano in
Current site
Google Scholar
PubMed
Search for other papers by Kim Andriano in
Current site
Google Scholar
PubMed
Gilbert Lefèvre
Gilbert Lefèvre
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Gilbert Lefèvre in
Current site
Google Scholar
PubMed
Search for other papers by Gilbert Lefèvre in
Current site
Google Scholar
PubMed
Patricia Ibarra De Palacios
Patricia Ibarra De Palacios
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Patricia Ibarra De Palacios in
Current site
Google Scholar
PubMed
Search for other papers by Patricia Ibarra De Palacios in
Current site
Google Scholar
PubMed
Blaise Genton
Blaise Genton
Medical Department, Swiss Tropical Institute, Basel, Switzerland; CIBIC, Centro de Investigaciones Bioclínicas, Bogotá, Colombia; Department of Tropical Medicine and Infectious Diseases, University of Munich, Munich, Germany; University Hospital Charité, Berlin, Germany; Tropeninstitut Berlin, Berlin, Germany; Hôpital Cantonal, Geneva, Switzerland; Hôpital Pitié-Salpêtrière, Paris, France; Department of Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Novartis Pharma AG, Basel, Switzerland; Travel Clinic, Medical Outpatient Clinic, Lausanne, Switzerland
Search for other papers by Blaise Genton in
Current site
Google Scholar
PubMed
Search for other papers by Blaise Genton in
Current site
Google Scholar
PubMed
The efficacy and safety of artemether-lumefantrine for the treatment of malaria in nonimmune populations are not well defined. In this study, 165 nonimmune patients from Europe and non-malarious areas of Colombia with acute, uncomplicated falciparum malaria or mixed infection including P. falciparum were treated with the six-dose regimen of artemether-lumefantrine. The parasitologic cure rate at 28 days was 96.0% for the per protocol population (119/124 patients). Median times to parasite clearance and fever clearance were 41.5 and 36.8 hours, respectively. No patient had gametocytes after Day 7. Treatment was well tolerated; most adverse events were mild to moderate and seemed to be related to malaria. There were few serious adverse events, none of which were considered to be drug-related. No significant effects on ECG or laboratory parameters were observed. In conclusion, the six-dose regimen of artemether-lumefantrine was effective and well tolerated in the treatment of acute uncomplicated falciparum malaria in nonimmune patients.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K, 2005. Malaria risk in travelers. Emerg Infect Dis 11 :436–441.
-
2
Ranque S, Marchou B, Malvy D, Adehossi E, Laganier R, Tissot-Dupont H, Lotte A, Dydymsky S, Durant J, Stahl JP, Bosseray A, Gaillat J, Sotto A, Cazorla C, Ragneau JM, Brouqui P, Delmont J, Infectio-Sud Group, 2005. Treatment of imported malaria in adults: a multicentre study in France. QJM 98 :737–743.
-
3
Bradley DJ, Bannister B, 2003. Health protection Agency Advisory Committee on malaria prevention for UK travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Public Health 6 :180–199.
-
4
Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, Vranjes N, Bergqvist Y, Ericsson O, Hellgren U, Rombo L, Mannino S, Handschin J, Sturchler D, 1996. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments: stereochemistry and compliance. Trop Med Int Health 1 :485–494.
-
5
Patel SN, Kain KC, 2005. Atovaquone-proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther 3 :849–861.
-
6
Mayxay M, Khanthavong M, Lindegardh N, Kiola S, Barends M, Pongvongsa T, Yapon R, Annerberg A, Phompida S, Phetsouvan R, White NJ, Newton PN, 2004. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether- lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic. Clin Infect Dis 39 :1139–1147.
-
7
Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R, 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug–resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 64 :247–256.
-
8
Van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ, 1999. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 61 :964–967.
-
9
Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Treeprasertsuk S, Kano S, Brittenham GM, Looareesuwan S, 2003. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian Public Health. 34 :316–321.
-
10
Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI, 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99 :459–467.
-
11
Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, Bosman A, Moyou-Somo R, Nahimana A, Nyarushatsi JP, Barihuta T, Mizero L, Ndaruhutse J, Delacollette C, Ringwald P, Kamana J, 2004. Efficacy of artemisinin derivative combination therapy for the treatment of uncomplicated falciparum malaria in Burundi; Efficacité de combinaisons thérapeutiques avec des dérivés de lart ’ émisinine dans le traitement de l’accès palustre non-compliqué au Burundi. Trop Med Int Health 9 :673–679.
-
12
Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Björkman A, 2005. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41 :1079–1086.
-
13
Mutabingwa TK, Anthony D, Heller A, Hallet R, Ahmed J, Drakely C, Greenwood BM, Whitty CJM, 2005. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodia-quine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 :1476–1482.
-
14
World Health Organization, 2000. Management of Severe Malaria. A Practical Handbook. Second Edition. Geneva: World Health Organization.
-
15
Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J, 1998. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129 :241–244.
-
16
Bazett JC, 1920. An analysis of time relation of electrocardiograms. Heart 7 :353–367.
-
17
Fridericia LS, 2003. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 8 :343–351.
-
18
Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, Chongsuphajaisiddhi T, White N, 2001. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg 65 :614–622.
-
19
Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M, 2000. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 56 :375–381.
-
20
Krippner R, Staples J, 2003. Suspected allergy to artemether-lumefantrine treatment of malaria. J Travel Med 10 :303–305.
-
21
Vatan R, Pistone T, Millet P, Etienne G, Mercie P, Longy-Boursier M, Malvy D, 2006. Retrospective analysis of 107 imported adult cases of malaria. Experience report of uncomplicated falciparum malaria treatment in adults with oral atovaquone-proguanil. Presse Med. Apr 35 :571–577.
-
22
Hitani A, Nakamura T, Ohtomo H, Nawa Y, Kimura M, 2006. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan. J Infect Chemother 12 :277–282.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 44 | 44 | 12 |
| Full Text Views | 323 | 115 | 2 |
| PDF Downloads | 144 | 55 | 4 |